Neuroimaging Predictors of Antidepressant Treatment Outcome
Drug: Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
|Study Design:||Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
- Blood-oxygen-level dependent (BOLD) responses during the Real-Time Neurofeedback Task. [ Time Frame: BOLD responses will be assessed at baseline and depression severity will be assessed at baseline ]
- Depression severity assessed with several depressive questionnaires. [ Time Frame: Every two weeks until the end of the trial (16 weeks total), or until the participants leave the study. ]
- Neuropsychological functioning of patients with depression [ Time Frame: At baseline ]
Affect processing: Emotional Words Task and Facial Emotion Perception test. Attention and Inhibitory Control: Parametric Go/NoGo, Trail Making test and the Stroop Color Word test .
Inferential Reasoning (including cost-benefit analysis): Delayed Discounting of Money Rewards, Iowa Gambling Task, Common Difference effect gambling task and the WCST.
- BDNF Val66Met single nucleotide polymorphism(SNP)genotyping [ Time Frame: At baseline ]5ml of blood drawn per participants will be used for genotyping
|Study Start Date:||July 2013|
|Study Completion Date:||June 2014|
|Primary Completion Date:||June 2014 (Final data collection date for primary outcome measure)|
Experimental: Placebo and Citalopram
4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
Other Name: CelexaDrug: Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session
Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02000726
|United States, Michigan|
|Department of Psychiatry|
|Ann Arbor, Michigan, United States, 48108|